Open Menu

Meetings & Education

Research & Data

Practice & Patients

Career Development

News & Initiatives

Get Involved

A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer.

**Background:** Traditional immune checkpoint inhibitors have shown limited benefit in pancreatic ductal adenocarcinoma (PDAC) owing to non-redundant immune resistance mechanisms dominating the tumor microenvironment (TME). Transforming growth factor (TGF)-β and cluster of differentiation (CD)73-adenosine represent two major immunoregulatory and pro-tumorigenic pathways responsible for therapeutic resistance and progressive disease in PDAC. AGEN1423 (also known as dalutrafusp alfa and GS-1423) is a bifunctional, humanized, aglycosylated immunoglobulin G1 kappa antibody that selectively inhibits CD73-adenosine production and neutralizes active TGF-β signaling. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. We hypothesize that the combination of AGEN1423 with BOT can rescue T-cell functional activity leading to responses in advanced PDAC.

Methods: An investigator-initiated open label Phase 2 study to evaluate the safety, tolerability, and initial efficacy of BOT + AGEN1423 +/- chemotherapy in patients with metastatic PDAC (NCT05632328). In cohort 1, 12 patients with metastatic PDAC with disease progression to at least one line of treatment will receive AGEN1423 30mg/kg IV Q2W for 4 doses + BOT 150mg IV Q6W ongoing for up to 2 years. If the combination is considered safe and tolerable, and objective response is achieved in at least 1 subject, the study will proceed to Cohort 2. In Cohort 2, 12 additional patients with disease progression on first-line fluorouracil-based chemotherapy will be enrolled to receive second-line gemcitabine and nab-paclitaxel in combination with AGEN1423 30mg/kg IV Q2W for 4 doses + BOT 150mg IV Q6W. Key eligibility criteria include histologically or cytologically confirmed metastatic pancreatic adenocarcinoma, age ≥18 years, Eastern Cooperative Oncology Group (ECOG) performance status ≤1, adequate organ function, and measurable disease by RECISTv1.1. A pre-treatment and on-treatment tumor biopsy will be obtained for translational studies. The primary endpoint is to estimate the objective response rate (ORR) according to RECISTv1.1 criteria. Secondary endpoints include safety and tolerability as defined by the incidence of AEs as assessed according to CTCAE v5, disease control rate (DCR), progression-free survival (PFS), and overall survival (OS). Translational endpoints include the characterization of the transcriptional signatures in paired biopsies obtained before and on-treatment with BOT + AGEN1423, as well as the changes in cell composition of the TME following treatment using multiplexed immunofluorescence spatial technology. Enrolment has started and accrual is anticipated to complete in Q4 2025.

Disclaimer

Author Details

Bruno Bockorny

Beth Israel Deaconess Medical Center, Boston, MA

Authors chevron_right

Associated Organizations chevron_right

Abstract Details

Meeting

2025 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

View MoreAbstract Disclosure
open_in_new

iframe

Company Logo

Your Privacy

ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.

Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.

For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.

Allow All

Essential Website Cookies

Always Active

These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.

They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.

You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.

Cookies Details‎

Performance and Functionality Cookies

These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.

All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.

Cookies Details‎

Personalization and Analytics Cookies

These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.

These cookies may be set by us or by third party providers whose services we have added to our websites.

These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.

Cookies Details‎

Advertising Cookies and Social Media Cookies

Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.

Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.

These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.

If you do not allow these cookies, you may experience less targeted advertising.

Cookies Details‎

Back Button

Search Icon

Filter Icon

Clear

checkbox labellabel

ApplyCancel

ConsentLeg.Interest

checkbox labellabel